A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis.

[1]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[2]  J. Kempen,et al.  Cyclosporine for ocular inflammatory diseases. , 2010, Ophthalmology.

[3]  A. Dick,et al.  Mycophenolate mofetil for the treatment of uveitis. , 2008, American journal of ophthalmology.

[4]  D. Jabs.  Epidemiology of Uveitis , 2008, Ophthalmic epidemiology.

[5]  A. Dick,et al.  Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. , 2007, Ophthalmology.

[6]  D. Hricik,et al.  Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[7]  S. Lubitz,et al.  Long-term results of tacrolimus monotherapy in cardiac transplant recipients. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[9]  J. Squifflet,et al.  Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study , 2005, Transplantation.

[10]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[11]  Douglas A Jabs,et al.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. , 2005, American journal of ophthalmology.

[12]  A. Dick,et al.  Quality of life and visual function in patients with intermediate uveitis , 2005, British Journal of Ophthalmology.

[13]  Douglas A Jabs,et al.  Improving the reporting of clinical case series. , 2005, American journal of ophthalmology.

[14]  J. Forrester,et al.  Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. , 2005, Archives of ophthalmology.

[15]  C. Margarit,et al.  Corticosteroid‐free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  A. Okada.  Immunomodulatory Therapy for Ocular Inflammatory Disease: A Basic Manual and Review of the Literature , 2005, Ocular immunology and inflammation.

[17]  Fred W Fitzke,et al.  How sensitive to clinical change are ETDRS logMAR visual acuity measurements? , 2003, Investigative ophthalmology & visual science.

[18]  D. Elbourne,et al.  Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial , 2002, The Lancet.

[19]  A. Dick,et al.  CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. , 2001, Investigative ophthalmology & visual science.

[20]  P. Blankestijn,et al.  Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. , 2001, Journal of the American Society of Nephrology : JASN.

[21]  R. V. Van Gelder,et al.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. , 2000, American journal of ophthalmology.

[22]  L. Rydén.  Results of the ATLAS study. , 1999, International journal of clinical practice. Supplement.

[23]  S. Jensik.  Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. , 1998, Transplantation proceedings.

[24]  W. Padberg,et al.  Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. , 1998, Transplantation proceedings.

[25]  N. Black.  CONSORT , 1996, The Lancet.

[26]  A Rothova,et al.  The possible impact of uveitis in blindness: a literature survey. , 1996, The British journal of ophthalmology.

[27]  S. Ohno,et al.  FK506 treatment of noninfectious uveitis. , 1994, American journal of ophthalmology.

[28]  B. Griffith,et al.  A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. , 1994, Transplantation.

[29]  D. Faulds,et al.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. , 1993, Drugs.

[30]  G. Gores,et al.  SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS , 1993, Transplantation.

[31]  M. Mochizuki,et al.  A clinical trial of FK506 in refractory uveitis. , 1993, American journal of ophthalmology.

[32]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. , 1987, The Journal of antibiotics.

[33]  H. Kaufman.  OCULAR INFLAMMATORY DISEASE. , 1964, The New England journal of medicine.

[34]  J. Forrester,et al.  Practical Manual of Intraocular Inflammation , 2008 .

[35]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[36]  J. Jacobs,et al.  Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2002, Annals of Internal Medicine.

[37]  J. Forrester.  Posterior Segment Intraocular Inflammation : Guidelines , 1998 .

[38]  G. Baarsma,et al.  Epidemiology of uveitis. , 1995, Current opinion in ophthalmology.

[39]  M. Okuhara,et al.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. , 1987, The Journal of antibiotics.